Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Precision BioSciences, Inc.

< Previous 1 2 3 4 5 Next >
Precision BioSciences Announces Return of Programs and Conclusion of Collaboration with Prevail Therapeutics
From Precision BioSciences, Inc.
Via Business Wire
Tickers DTIL
Precision BioSciences Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Provides Business Update
From Precision BioSciences, Inc.
Via Business Wire
Tickers DTIL
Precision BioSciences to Report Fourth Quarter and Fiscal Year 2023 Results on March 27, 2024
From Precision BioSciences, Inc.
Via Business Wire
Tickers DTIL
Precision BioSciences Announces MHRA Approval for Partner iECURE to Expand Phase 1/2 Clinical Trial of ARCUS Gene Editing Program in OTC Deficiency
From Precision BioSciences, Inc.
Via Business Wire
Tickers DTIL
Precision BioSciences Announces $40.0 Million Offering of Common Stock and Warrants
From Precision BioSciences, Inc.
Via Business Wire
Tickers DTIL
Precision BioSciences Announces Proposed Public Offering of Common Stock and Warrants
From Precision BioSciences, Inc.
Via Business Wire
Tickers DTIL
Precision BioSciences Announces Non-Exclusive Patent License Agreement with Caribou Biosciences
From Precision BioSciences, Inc.
Via Business Wire
Tickers DTIL
Precision BioSciences Promotes Naresh Tanna to Vice President of Investor Relations
From Precision BioSciences, Inc.
Via Business Wire
Tickers DTIL
Precision BioSciences Receives Initial $7.5 Million Cash Payment and Equity Investment from TG Therapeutics for Azel-Cel in Treatment of Autoimmune Diseases
From Precision BioSciences, Inc.
Via Business Wire
Tickers DTIL
Precision BioSciences to Effect a Reverse Stock Split
From Precision BioSciences, Inc.
Via Business Wire
Tickers DTIL
Precision BioSciences Completes License Deal with TG Therapeutics for Cell Therapy Azer-Cel in Treatment of Autoimmune Diseases
From Precision BioSciences, Inc.
Via Business Wire
Tickers DTIL
Precision BioSciences Announces Approval of First Clinical Trial Application of ARCUS Gene Insertion Program by Partner iECURE
From Precision BioSciences, Inc.
Via Business Wire
Tickers DTIL
Precision BioSciences Announces Publication in Nature Metabolism Supporting ARCUS® In Vivo Gene Editing as a Potentially Curative Treatment for Mitochondrial Diseases
From Precision BioSciences, Inc.
Via Business Wire
Tickers DTIL
Precision BioSciences to Present at Hep-DART 2023
From Precision BioSciences, Inc.
Via Business Wire
Tickers DTIL
Precision BioSciences Announces Grant of Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
From Precision BioSciences, Inc.
Via Business Wire
Tickers DTIL
Precision BioSciences Presents Late-Breaking Data Highlighting Preclinical Efficacy and Safety of PBGENE-HBV for Chronic Hepatitis B at AASLD’s The Liver Meeting 2023
From Precision BioSciences, Inc.
Via Business Wire
Tickers DTIL
Precision BioSciences to Present at Upcoming Sidoti Conference
From Precision BioSciences, Inc.
Via Business Wire
Tickers DTIL
Precision BioSciences Announces Late-Breaking Poster Presentation at the American Association for the Study of Liver Diseases (AASLD) Annual Meeting
From Precision BioSciences, Inc.
Via Business Wire
Tickers DTIL
Precision BioSciences Reports Third Quarter 2023 Financial Results and Provides Business Update
From Precision BioSciences, Inc.
Via Business Wire
Tickers DTIL
Precision BioSciences to Report Third Quarter Results on November 7, 2023
From Precision BioSciences, Inc.
Via Business Wire
Tickers DTIL
Precision BioSciences Presents Preclinical Data Highlighting Capabilities of ARCUS for Gene Insertion and Excision at the European Society of Gene & Cell Therapy (ESGCT) 30th Annual Congress
From Precision BioSciences, Inc.
Via Business Wire
Tickers DTIL
Precision BioSciences to Present at Upcoming H.C. Wainwright 4th Annual Hepatitis B Virus Conference
From Precision BioSciences, Inc.
Via Business Wire
Tickers DTIL
Precision BioSciences to Present at the European Society of Gene & Cell Therapy (ESGCT) 30th Annual Congress
From Precision BioSciences, Inc.
Via Business Wire
Tickers DTIL
Precision BioSciences Receives U.S. Patent Allowance Covering PBGENE-PMM for m.3243-Associated Mitochondrial Diseases
From Precision BioSciences, Inc.
Via Business Wire
Tickers DTIL
Precision BioSciences Hosts Virtual R&D Day Highlighting its Proprietary ARCUS Technology and Recent In Vivo Gene Editing Program Developments
From Precision BioSciences, Inc.
Via Business Wire
Tickers DTIL
Precision BioSciences to Attend and Present at Upcoming September Investor Conferences
From Precision BioSciences, Inc.
Via Business Wire
Tickers DTIL
Precision BioSciences to Host In Vivo Gene Editing R&D Day on September 12, 2023
From Precision BioSciences, Inc.
Via Business Wire
Tickers DTIL
Precision BioSciences Completes Strategic Transaction with Imugene for Azer-Cel in Cancer
From Precision BioSciences, Inc.
Via Business Wire
Tickers DTIL
Precision BioSciences Reports Second Quarter 2023 Financial Results and Provides Business Update
From Precision BioSciences, Inc.
Via Business Wire
Tickers DTIL
Precision BioSciences to Report Second Quarter Results on August 4, 2023
From Precision BioSciences, Inc.
Via Business Wire
Tickers DTIL
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.